TSTeresa Sánchez-Gutiérrez

Teresa Sánchez-Gutiérrez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teresa Sánchez-Gutiérrez has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: Reviews in psychiatry 2023: schizophrenia

    by Massimo Tusconi, Dennis Kätzel, Teresa Sánchez-Gutiérrez

    Schizophrenia is a severe psychiatric disorder that imposes a considerable burden on patients, their families, and society as a whole (1). The fact that the burden of schizophrenia is compounded by the insufficient efficacy of available treatment options has motivated a wide range of clinical and pre-clinical research endeavors. The contributions to this Research Topic represent this diversity of research and thereby mirror the complexity of the disorder itself. Schizophrenia is a nosological entity with a very heterogeneous spectrum of deficits. These are categorically identified as positive, negative, and cognitive symptoms (2). Moreover, recent discoveries regarding inherent biomarkers (3) and neurodevelopmental disease progression (4) increasingly suggest possible overlap with other psychiatric disorders, such as bipolar disorder (5-7). This overlap ranges from genetic (5) and environmental (6, 7) risk factors to pathophysiological mechanisms and symptoms (8, 9). Recognition of symptomatologic patterns and familiarities between disorders may provide a more precise diagnostic framing and better management of clinical aspects. It is important to identify factors that can support the differential diagnosis and allow the most appropriate treatment for Schizophrenia patients who represent nosographic clusters of considerable complexity (10). Thus, an overview of both quantitative and qualitative data on clinical characteristics and treatment outcomes may elucidate the patterns and mechanisms of Schizophrenia pathogenesis and its modifiability (11, 12). In this regard, the reviews included in this Research Topic allow for an in-depth reflection on several aspects of mental pathology in general and highlight possible future directions of scientific advancement (13). Several reviews have examined the effectiveness of non-pharmacological treatment options for Schizophrenia. For example, in parallel with standard psychosocial and pharmacological treatment, the use of virtual reality offers new solutions that can lead to appreciable results in various functional and symptomatic domains. The review by Holopainen et al. on the efficacy of immersive extended reality (XR) interventions on different symptom domains of Schizophrenia spectrum disorders showed that treatment gamification allows for greater patient engagement in therapy, harnessing the motivation of novelty represented by this virtuous technology. Furthermore, unlike drug treatment which is often associated with many side effects and stigma, this therapeutic approach is believed to be devoid of such drawbacks and likely to provide a favorable end-user experience and Frontiers in Psychiatry frontiersin.org 01